Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:805-14.
doi: 10.2147/PPA.S29092. Epub 2012 Nov 8.

Adherence to lipid-lowering treatment: the patient perspective

Manuela Casula  1 , Elena Tragni, Alberico Luigi Catapano
Affiliations

Adherence to lipid-lowering treatment: the patient perspective

Manuela Casula et al. Patient Prefer Adherence. 2012.

Abstract

Despite the widespread prescription of highly effective lipid-lowering medications, such as the HMG-CoA reductase inhibitors (statins), a large portion of the population has lipid levels higher than the recommended goals. Treatment failures have been attributed to a variety of causes but the most important is likely to be poor adherence to therapy in the form of irregular or interrupted intake and the high frequency of discontinuation or lack of persistence. Adherence is a multidimensional phenomenon determined by the interplay of patient factors, physician factors, and health care system factors. Patients' knowledge and beliefs about their illness, motivation to manage it, confidence in their ability to engage in illness-management behaviors, and expectations regarding the outcome of treatment and the consequences of poor adherence interact to influence adherence behavior. Patient-related factors account for the largest incremental explanatory power in predicting adherence. This article provides an overview of this critical issue, focusing on patient role in determining adherence level to lipid-lowering therapy.

Keywords: health behavior; hyperlipidemia/drug therapy; medication adherence; patient preference.

PubMed Disclaimer

References

    1. World Health Organization. Global Status Report on Noncommunicable Diseases. Geneva: World Health Organization; 2010. [Accessed October 15, 2012]. Available from: http://www.who.int/nmh/publications/ncd_report2010/en/
    1. Centers for Disease Control and Prevention (CDC) Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol – United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011;60(4):109–114. - PubMed
    1. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U for EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–940. - PubMed
    1. Straka RJ, Taheri R, Cooper SL, Tan AW, Smith AC. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy. 2001;21(7):818–827. - PubMed
    1. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006;12(Suppl 15):S405–S411. - PubMed